Caplin Point Laboratories share news and announcements
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,222.00down ₹27.10 (1.20%)BSE ₹2,222.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,249.10.
52-week range of traded prices to 23 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,890 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 76,90447.0% delivered
Caplin Point Laboratories share news and announcements
496 announcements, routine notices left out, newest first. Page 8 of 10.
Jan 2019
2 Jan · Board meeting
Dec 2018
Nov 2018
30 Nov · Updates
19 Nov · Board meeting
12 Nov · Board meeting
Oct 2018
Sep 2018
Aug 2018
Jul 2018
Jun 2018
1 Jun · Updates
May 2018
Apr 2018
Mar 2018
12 Mar · Board meeting
1 Mar · Board meeting
Feb 2018
15 Feb · Disclosure
7 Feb · Disclosure
Jan 2018
Nov 2017
9 Nov · Board meeting
Oct 2017
Sep 2017
Aug 2017
8 Aug · Legal
Exchange has sought clarification from Caplin Point Laboratories Limited with respect to announcement dated 07-Aug-2017, regarding "Outcome of Board Meeting held on August 07, 2017."On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);2. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.7 Aug · Board meeting
Jul 2017
May 2017
17 May · Results